About Alnylam
Alnylam is a publicly listed company based in Cambridge (United States) founded in 2002 by Paul Schimmel, Phillip Sharp, and John Clarke. RNA interference-based therapeutics are developed for multiple disorders. It operates in the Healthcare and Technology sectors. Alnylam has raised $17 million across 7 funding rounds from investors including Blackstone, Arch Venture Partners and Atlas Venture. The company has 2,230 employees. Alnylam has completed 2 acquisitions, including Nucleonics and Sirna Therapeutics. Its chief executive, as recorded, is John Maraganore. Its website alnylam.com draws about 78 thousand monthly visits. Its focus areas include Life Sciences, Gene Therapy, RNA and siRNA. Its legal entity is ALNYLAM PHARMACEUTICALS, INC. Its competitors include BridgeBio, Spark Therapeutics and Insitro; 3 of its 3 listed competitors have raised funding.
Company details
Alnylam was founded in 2002 and is headquartered in Cambridge, United States. RNA interference therapeutics are developed for genetic and other disorders within the biotechnology sector. The pipeline encompasses treatments for hereditary ATTR amyloidosis, acute hepatic porphyria, and hypercholesterolemia. Further development targets cardiometabolic conditions, infectious diseases, central nervous system disorders, and ocular diseases. Operations emphasize research and drug advancement in these areas.
- Annual Revenue$3.71 B (USD)65.19as on Dec 31, 2025
- Net Profit$313.75 M (USD)as on Dec 31, 2025
- EBITDA$557.24 M (USD)as on Dec 31, 2025
- Total Equity Funding$17M (USD)
in 7 rounds
- Latest Funding Round$150M (USD), Post-IPO
Aug 2020
- InvestorsBlackstone
& 7 more
- Employee Count2,230
- Investments & AcquisitionsNucleonics
& 1 more
Apps and channels of Alnylam
its YouTube channel Alnylam Pharmaceuticals has 2.76K subscribers and 30 videos.
Videos from Alnylam
The most watched videos on Alnylam's YouTube channel, Alnylam Pharmaceuticals (2.76K subscribers). Click a video to play it here.
More on Alnylam Pharmaceuticals.
Funding Insights of Alnylam
Alnylam has successfully raised a total of $17M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 7
- Last Round Post-IPO — $150M
- First Round $17M
(Aug 2002)
- Investors Count 8
All 7 funding rounds of Alnylam with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $150M | Post-IPO | – | – | |
| Apr 2020 | $100M | Post-IPO | – | – | |
| Nov 2017 | $700M | Post-IPO | – | – | – |
| Jan 2014 | $700M | Post-IPO | – | – | |
| Oct 2007 | $1.42M | Grant | – | – | |
| Oct 2006 | $24.6M | Post-IPO | – | – | |
| Aug 2002 | $17M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Alnylam
Alnylam has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Arch Venture Partners and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Life science & tech focused VC firm investing in early stage companies in the US | cardinalpartners.com | Princeton, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Biopharmaceutical products for rare genetic diseases are developed and supplied. | 1996 | genzyme.com | Boston, United States | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Alnylam
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alnylam
577 people are tracked at Alnylam (304 in leadership, 8 in board & advisors, 265 in team); the tracked headcount is 2,230.
| Name | Role | Group |
|---|---|---|
Paul Schimmel | Co-Founder | Leadership |
Phillip Sharp | Co-Founder | Leadership |
John Clarke | Co-Founder | Leadership |
John Maraganore | CEO | Leadership |
Corey Gray | Head Of Insights And Analytics, Senior Director | Leadership |
Monika M. | Head Of Clinical Science | Leadership |
Yvonne Greenstreet | CEO | Leadership |
Piyush Sharma | Chief Ethics & Compliance Officer | Leadership |
Vanessa Etienne-Louis | Sr. Executive Assistant To The Chief Legal Officer | Leadership |
Luke Ward | Director, Statistical Genetics | Leadership |
John Mariano | Head Of Artificial Intelligence, Data And Engineering | Leadership |
Bertha Vilela | Vp, Hr, International And Partner & Emerging Markets | Leadership |
Joan Orellana | Associate Director Quality Assurance | Leadership |
Joseph Barry | Associate Director, Data Sciences | Leadership |
David Jones | VP Finance Cemea | Leadership |
Elvis J. Alonso | Vice President, Research And Early Development Operations | Leadership |
Lauren Dietze | Senior Director, Human Resources | Leadership |
Lawrence Egan | VP Strategic Technologies | Leadership |
Muthiah Manoharan | Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist | Leadership |
Nancy Silliman | Senior Vice President, Data Science, Statistics, And Epidemiology | Leadership |
557 more people are available in the full profile.
Complete people profiles for Alnylam
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alnylam
Alnylam is a publicly listed company on the NASDAQ with ticker symbol ALNY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 May 2004
- Listed onNASDAQ: ALNY
- Listed entityAlnylam Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS02043Q1076
- Share price$223.82 (-1.41% on the day) · 2026-10-13
- Market capitalisation$29.95B
- Price to earnings37.8
- EPS (diluted, trailing year)$5.92
- Volume (last session)1,119,026
Financials of Alnylam
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.71B | $313.8M | $557.2M |
| 2024 | $2.25B | -$278.2M | -$120.2M |
| 2023 | $1.83B | -$440.2M | -$228.1M |
| 2022 | $1.04B | -$1.13B | -$740.6M |
| 2021 | $844.3M | -$852.8M | -$661.1M |
Detailed financial statements for Alnylam
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alnylam
Alnylam has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Nucleonics and Sirna Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops RNAi-based therapies | sirna.com | San Francisco, United States | 1992 | Jan 2014 | $175M | |
RNAi therapeutics for viral diseases including Hepatitis-B were developed. | nucleonicsinc.com | Langhorne, United States | 2001 | Dec 2008 | •••• |
Complete acquisition details for Alnylam
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alnylam
6 dated milestones of Alnylam across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Alnylam is founded.
- Funding First funding round of $17.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Nucleonics.
- Acquisition Acquires Sirna Therapeutics.
- Funding Latest funding round, Post-IPO, of $150.0M.
Competitors of Alnylam
Alnylam has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Insitro.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. |
Detailed competitors of Alnylam
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alnylam
The website of Alnylam (alnylam.com) receives about 77.8K visits a month.
- Monthly visits77.8K
▲ 17.2% vs previous month
Websites whose visitors overlap most with Alnylam. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
isispharm.com | isispharm.com | 100% | – | ||
| regulusrx.com | 100% | View details | |||
| cequentpharma.com | 84% | View details | |||
rxipharma.com | rxipharma.com | 83% | – | ||
| silence-therapeutics.com | 82% | 13.8K | #1,916,504 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Alnylam
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Alnylam (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alnylam
Complete news archive for Alnylam
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alnylam
Alnylam was founded in 2002.
Alnylam is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John Maraganore is the CEO of Alnylam, as recorded in our data.
Alnylam is a funded company, having raised a total of $17M across 7 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Aug 2002.
Alnylam has 2,230 employees.
Annual revenue of Alnylam is $3.71B as on Dec 31, 2025.
Alnylam was founded in 2002 and is headquartered in Cambridge, United States. RNA interference therapeutics are developed for genetic and other disorders within the biotechnology sector. The pipeline encompasses treatments for hereditary ATTR amyloidosis, acute hepatic porphyria, and hypercholesterolemia. Further development targets cardiometabolic conditions, infectious diseases, central nervous system disorders, and ocular diseases. Operations emphasize research and drug advancement in these areas.
Alnylam's top competitors include Spark Therapeutics, BridgeBio and Insitro.
Yes, Alnylam is publicly traded on NASDAQ under the ticker symbol ALNY.
Alnylam has made 2 acquisitions, including Nucleonics, and Sirna Therapeutics.
Alnylam has 8 investors. Key investors include Blackstone, Arch Venture Partners, Atlas Venture, Genzyme, and Abingworth.
Alnylam operates through Alnylam Pharmaceuticals, Inc..